About Us
SCROLL
Partnership
Adhering to an open collaboration mindset, Skye Medicine builds broad partnerships with academia, clinical research sites and industry partners to drive innovation and industrial translation of cellular immunotherapy.
Lead Investors
Seed Round
Founded in 2003, Hony Capital is a leading comprehensive investment-management group in China, with assets under management exceeding RMB 120 billion. Its limited partners include world-class long-term capital such as Goldman Sachs, Temasek and the National Social Security Fund of China. With years of deep focus on healthcare and hard-technology sectors, Hony Capital boasts rich empowering experience in incubating innovative biotech enterprises and advancing their industrialization.
Seed Round
Med-Fine Capital is a sector-focused venture-capital fund dedicated to healthcare and life sciences. It targets cutting-edge areas including cell therapy, novel drugs and medical devices. The fund has invested in more than 60 innovative biopharmaceutical companies, and provides in-depth support for biotech start-ups in pipeline development and clinical translation.
Co-Investors
Suzhou Venture Capital, CS Capital, Yingxian Investment, Addor Capital, Haohai Qibang, Shanghai Jinxiang etc.
These are professional equity-investment institutions deeply rooted in China’s biopharmaceutical sector. They continuously back early-stage innovative biotech companies and deliver comprehensive support covering industrial-resource matchmaking, clinical collaboration and commercial-strategy planning.
